Objective: to explore the clinical treatment measures and therapeutic effects of functional uterine bleeding. Methods: from January 2020 to January 2022, 20 patients with functional uterine bleeding were selected and ...Objective: to explore the clinical treatment measures and therapeutic effects of functional uterine bleeding. Methods: from January 2020 to January 2022, 20 patients with functional uterine bleeding were selected and randomly divided into the control group and the observation group according to the coin toss method. The number of patients in each group was n 25. Twenty-five patients in the control group were treated with medroxyprogesterone and 25 patients in the observation group were treated with mifepristone. After two different drug treatments, the two groups were compared. Results: twenty-five patients in the control group were treated with progesterone and 25 patients in the observation group were treated with mifepristone. The total effective rate of 25 patients in the observation group was 96.00%, while that of 25 patients in the control group was 72.00%. Conclusion: mifepristone can inhibit endometrial growth, promote menopause and correct anemia in patients with functional uterine bleeding, and it has less side effects on patients. It is an ideal drug for the treatment of menopausal dysfunctional uterine bleeding, and it is worthy of being widely used clinically.展开更多
文摘Objective: to explore the clinical treatment measures and therapeutic effects of functional uterine bleeding. Methods: from January 2020 to January 2022, 20 patients with functional uterine bleeding were selected and randomly divided into the control group and the observation group according to the coin toss method. The number of patients in each group was n 25. Twenty-five patients in the control group were treated with medroxyprogesterone and 25 patients in the observation group were treated with mifepristone. After two different drug treatments, the two groups were compared. Results: twenty-five patients in the control group were treated with progesterone and 25 patients in the observation group were treated with mifepristone. The total effective rate of 25 patients in the observation group was 96.00%, while that of 25 patients in the control group was 72.00%. Conclusion: mifepristone can inhibit endometrial growth, promote menopause and correct anemia in patients with functional uterine bleeding, and it has less side effects on patients. It is an ideal drug for the treatment of menopausal dysfunctional uterine bleeding, and it is worthy of being widely used clinically.
